CurifyLabs, a pioneering Finnish healthtech company, is proud to announce the successful raising of €6,700,000 in its latest funding round, marking a significant milestone in revolutionizing personalized medicine. Since its inception in 2021 by founders Charlotta Topelius and Niklas Sandler Topelius, CurifyLabs has dedicated itself to transforming the traditional, labor-intensive pharmaceutical compounding process into an efficient, automated, and accurate system through its groundbreaking Compounding System Solution (CSS). This innovative platform streamlines the production of non-sterile dosage forms such as tablets, troches, liquids, suppositories, vagitories, ointments, and capsules, offering a user-friendly, turnkey solution that empowers pharmacies and hospital pharmacies to manufacture personalized medications with unprecedented safety and precision.
The infusion of new capital will be pivotal in driving further advancements in CSS technology and expanding its footprint across both European and U.S. markets. CurifyLabs intends to invest the funds into scaling its robotic compounding capabilities, enhancing integrated quality control systems, and broadening its comprehensive formulation library—thus supporting a more agile and responsive approach to personalized care. Additionally, these resources will facilitate research and development initiatives aimed at refining manufacturing processes and improving cost-efficiency, ensuring that patients receive the most effective treatments at the point of care. By bolstering the supply chain and elevating manufacturing standards, CurifyLabs is taking proactive steps to meet ever-evolving healthcare demands, further establishing its leadership in the healthtech sector. This funding round not only underscores investor confidence in the company’s innovative approach but also heralds a new era in patient-centric pharmaceutical care.
